View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
  2. Company News
February 20, 2019updated 22 Mar 2022 7:14am

Novus Therapeutics begins dosing in otitis media drug trial

Novus Therapeutics has commenced dosing in a Phase IIa clinical trial of OP0201 for the treatment of otitis media, an inflammatory disease affecting the middle ear.

Novus Therapeutics has commenced dosing in a Phase IIa clinical trial of OP0201 for the treatment of otitis media, an inflammatory disease affecting the middle ear.

Free Whitepaper
img

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

OP0201 is a drug-device combination that consists of a formulation of surfactant dipalmitoylphosphatidylcholine and a spreading agent called cholesteryl palmitate, suspended in a propellant.

The drug is administered intranasally using a pressurised metered-dose inhaler (pMDI). It is meant to restore the normal physiologic activity of the Eustachian tube (ET), which connects the middle ear to the back of the nasopharynx.

The exploratory Phase IIa trial, named OP0201-C-006, is intended to assess the safety, tolerability, and efficacy of a daily 20mg dose of OP0201 as an adjunct to oral antibiotics over ten consecutive days.

“This exploratory Phase IIa study will help us to better understand the potential benefits of OP0201 when used as an adjunct to oral antibiotics.”

OP0201-C-006 is a randomised, double-blind, placebo-controlled, parallel-group trial will be conducted in 50 paediatric patients aged 6-24 months at a single site in the US.

Novus Therapeutics president Catherine Turkel said: “Acute otitis media affects millions of people every year, particularly young children who account for more than half of the incident cases annually.

“This exploratory Phase IIa study will help us to better understand the potential benefits of OP0201 when used as an adjunct to oral antibiotics, as well as help us plan our future otitis media clinical trials.”

Primary outcome measures of the trial are an evaluation of safety in the form of adverse effects, as well as efficacy measured as otoscopy.

The study will also monitor secondary outcome measures such as proportion of patients with no middle ear effusion, and those with abnormal tympanogram.

Novus Therapeutics anticipates completing the trial by April this year.

Related Companies

Free Whitepaper
img

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena